Evidence map›Paper›PMID 24670820›Full record

ArticleScientific reports2014

Modelling mutational landscapes of human cancers in vitro.

Magali Olivier, Annette Weninger, Maude Ardin, Hana Huskova, Xavier Castells, Maxime P Vallée, James McKay, Tatiana Nedelko, Karl-Rudolf Muehlbauer, Hiroyuki Marusawa and 5 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Magali OlivierMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, 69008 Lyon, France.
Annette WeningerGerman Cancer Research Center (Deutsches Krebsforschungszentrum), D69120 Heidelberg, Germany.
Maude ArdinMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, 69008 Lyon, France.
Hana HuskovaMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, 69008 Lyon, France.
Xavier CastellsMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, 69008 Lyon, France.
Maxime P ValléeGenetic Cancer Susceptibility Group, International Agency for Research on Cancer, 69008 Lyon, France.
James McKayGenetic Cancer Susceptibility Group, International Agency for Research on Cancer, 69008 Lyon, France.
Tatiana NedelkoGerman Cancer Research Center (Deutsches Krebsforschungszentrum), D69120 Heidelberg, Germany.
Karl-Rudolf MuehlbauerGerman Cancer Research Center (Deutsches Krebsforschungszentrum), D69120 Heidelberg, Germany.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
John AlexanderFaculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom.
Lee HazelwoodFaculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom.
Graham ByrnesBiostatistics Group, International Agency for Research on Cancer, 69008 Lyon, France.
Monica Hollstein1] German Cancer Research Center (Deutsches Krebsforschungszentrum), D69120 Heidelberg, Germany [2] Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom.
Jiri ZavadilMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, 69008 Lyon, France.
Centre International de Recherche sur le Cancer · FRUniversity of Leeds · GBHeidelberg University · DEGerman Cancer Research Center · DEKyoto University · JP

Funding

World Health Organization 001
6 · The paper itself

Abstract

Experimental models that recapitulate mutational landscapes of human cancers are needed to decipher the rapidly expanding data on human somatic mutations. We demonstrate that mutation patterns in immortalised cell lines derived from primary murine embryonic fibroblasts (MEFs) exposed in vitro to carcinogens recapitulate key features of mutational signatures observed in human cancers. In experiments with several cancer-causing agents we obtained high genome-wide concordance between human tumour mutation data and in vitro data with respect to predominant substitution types, strand bias and sequence context. Moreover, we found signature mutations in well-studied human cancer driver genes. To explore endogenous mutagenesis, we used MEFs ectopically expressing activation-induced cytidine deaminase (AID) and observed an excess of AID signature mutations in immortalised cell lines compared to their non-transgenic counterparts. MEF immortalisation is thus a simple and powerful strategy for modelling cancer mutation landscapes that facilitates the interpretation of human tumour genome-wide sequencing data.

Indexed as

MutationAnimalsCell Line, TransformedComputational BiologyDNA Mutational AnalysisExomeGenome-Wide Association StudyHigh-Throughput Nucleotide SequencingHumansIn Vitro TechniquesMiceNeoplasms

Identifiers

PMID24670820
PMCPMC5259794
OpenAlexW2032409312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.